JinHai Medical Narrows H1 Loss as Revenue Surges on Medical Device Pivot

JinHai Medical Technology (02225) announced a significant improvement in its financial performance for the first half of 2026, signaling that its strategic pivot to high-value medical devices is yielding substantial results. The company's revenue more than doubled and its net loss narrowed considerably, driven by explosive growth in its minimally invasive surgery division.

Financial Highlights

According to its mid-2026 earnings report, JinHai Medical's key performance metrics showed strong positive momentum:

• Revenue: Reached S$34.02 million, a 134.16% increase compared to the same period last year.
• Net Loss: The loss attributable to shareholders shrank by 57.46% year-over-year to S$4.36 million.
• Medical Device Sales: Revenue from this core segment surged 301.5% to S$25.43 million.

The company's successful transition is evident in its revenue mix, with minimally invasive surgical solutions and related medical products now accounting for 74.73% of total income. This marks a decisive shift from its legacy in traditional labor services.

Improved Operational and Balance Sheet Health

Ad

JinHai Medical also demonstrated progress in cost control and financial management. Administrative expenses were reduced to S$10 million from S$12.5 million in the prior-year period, primarily due to lower equity-based payments. The company's balance sheet strengthened, with its debt-to-asset ratio improving to 25.5% as of June 30, 2026, down from 28.7% at the end of 2025.

This improved financial stability provides a solid foundation for the company's ongoing investment in research and development. JinHai's product portfolio includes advanced 4K, 3D, and 8K endoscopy systems, positioning it to compete in the high-end medical device market.

Strategic Hires and Market Outlook

To accelerate its commercial expansion, the company appointed Ma Chengdong as its Chief Marketing Officer in August 2026. Ma brings nearly three decades of experience from senior marketing and sales roles at multinational giants like GE Healthcare and Medtronic, which is expected to enhance JinHai's market penetration and channel management.

The company's growth is supported by favorable industry trends in China and the broader Asia-Pacific region, including rising healthcare spending and a structural shift from open surgery to minimally invasive procedures. This creates a significant opportunity for domestic manufacturers like JinHai to gain market share, particularly in the high-end segment often dominated by imports.